ACRS

Aclaris Therapeutics, Inc.
CAPPED RATING

Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The Contract Research segment engages in the provision of laboratory services. The company also develops Zunsemetinib, an MK2 inhibitor for the treatment of moderate to severe rheumatoid and Psoriatic arthritis, and Hidradenitis suppurativa; and ATI-1777, a soft JAK 1/3 inhibitor for the treatment of moderate to severe atopic dermatitis. In addition, it develops ATI-2138, an ITK/TXK/JAK3 inhibitor as a potential treatment for T cell-mediated autoimmune diseases; Gut-Biased Program for inflammatory bowel disease; and ATI-2231, an MK2 inhibitor treatment for pancreatic and metastatic breast cancer. The company was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

Aclaris Therapeutics, Inc. (ACRS) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Growth (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
C
Factor Score 2.4 / 5.0
Growth
D-
Factor Score 1.0 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -5.2
EV / EBITDA N/A
Rev Growth YoY -55.1%
Gross Margin 0.0%
Price Return 3M -42.8%
Price Return 12M 55.4%
Catalyst Signal 0.00
Market Cap $571.8M
TTM Revenue $6.4M
Price / Sales 89.3
ROE -55.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 C (2.4) D- (1.0) C (2.3) C- (2.0) C+ (2.6) C- (2.1)
2026-11-10 C (2.3) D- (1.1) C (2.3) C (2.2) C+ (2.6) C- (2.1)
2026-11-03 C+ (2.5) D (1.4) C (2.4) C+ (2.5) C+ (2.7) C (2.3)
2026-10-27 C+ (2.6) D (1.4) C (2.4) B- (2.9) C+ (2.6) C (2.4)
2026-10-20 C+ (2.7) D (1.4) C (2.4) B- (2.9) C+ (2.6) C (2.4)
Page 1 of 8
…